1. In Vivo
  2. >>Deal-Making

Pulling Back The Curtain On Biopharma Partnering In Cell And Gene Therapies

Janssen, Biogen And Astellas Execs Discuss Portfolio Priorities

 
• By Mandy Jackson

Therapeutic areas and unmet needs drive big company decision-making about when and what technologies to bring in from external sources, executives explained during a panel at the 2020 Cell and Gene Therapy Meeting on the Mesa.

DNA

Cell and gene therapies often originate at small biopharmaceutical firms, but big pharma and large biotech companies continue to increase their investments in these new modalities when they see external innovations that fit within their research and development strategies. Therapeutic area priorities and unmet needs drive these business development decisions, according to executives from Janssen, Biogen, Inc. and Astellas Pharma, Inc.

Sanjaya Singh, vice president and global head at Janssen BioTherapeutics and Janssen Research & Development LLC (subsidiaries of Johnson...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

More from In Vivo

‘A Small Medtech Industry Ecosystem With An Outsized Global Influence’

 
• By Ashley Yeo

Entrepreneurialism is in the blood of Israel’s medtech innovators, but in a changing medtech world, the local ecosystem must address funding gaps and manufacturing and infrastructure needs. So says Ruti Alon, experienced Israeli medtech leader, investor and co-chair of the Biomed Israel conference.

Dealmaking Quarterly Statistics, Q2 2025

 
• By Maureen Riordan and Deanna Kamienski

During Q2, biopharma merger and acquisition deal value reached $24.6bn and drew in $60.7bn in potential deal value from alliances. Device company M&A values reached $223m, while in vitro diagnostics and research tools players’ M&A activity totaled $802m.

PBMs Tighten The Reins: Value Becomes The New Access Gatekeeper

 
• By Andrew Cox

Facing rising costs and tighter regulations, PBMs and insurers are accelerating the shift to value-based drug coverage, demanding stronger proof of therapeutic and economic benefit from pharma.